Comment from The National Catholic Bioethics Center
AnonymousOpposeAdvocacy
Summary: The National Catholic Bioethics Center (NCBC) opposes the petition to reduce or eliminate FDA safety regulations on mifepristone, arguing that such changes would exacerbate risks to women's health and violate ethical standards. They advocate for strengthening current safeguards, including mandatory in-person consultations, better reporting of adverse effects, and more comprehensive informed consent regarding alternatives and potential complications.
NCBC comments omitted 2nd attachment, resent all here: Comment Tracking Number: mdn-jxdr-8j88
The National Catholic Bioethics Center (NCBC), the most renown Catholic bioethics research, publication, consultation, and education center in the United States, submits the following comments in opposition to the above-referenced Citizen Petition. NCBC represents hundreds of health care professionals, consumers, ethicists, and health care administrators, thus impacting thousands of Americans who rely on the effective and ethical delivery of health care. This aforementioned petition seeks to reduce or eliminate the FDA’s current safety regulations on the chemical abortion drug mifepristone, specifically concerning the Risk Evaluation and Mitigation Strategy (REMS) and Elements to Assure Safe Use (EASU), including Prescriber, Patient, and Pharmacy Certification elements.